136 related articles for article (PubMed ID: 21892895)
1. Pharmacokinetic evaluation of pramipexole.
Antonini A; Calandrella D
Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1307-14. PubMed ID: 21892895
[TBL] [Abstract][Full Text] [Related]
2. Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.
Antonini A; Calandrella D
Neuropsychiatr Dis Treat; 2011; 7():297-302. PubMed ID: 21654875
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
6. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
7. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Perez Lloret S; Rascol O
Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole for the treatment of early Parkinson's disease.
Perez-Lloret S; Rey MV; Ratti L; Rascol O
Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
[TBL] [Abstract][Full Text] [Related]
11. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical studies of pramipexole: clinical relevance.
Hubble JP
Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
[TBL] [Abstract][Full Text] [Related]
13. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.
Cheah BC; Kiernan MC
IDrugs; 2010 Dec; 13(12):911-20. PubMed ID: 21154151
[TBL] [Abstract][Full Text] [Related]
14. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Ferger B; Buck K; Shimasaki M; Koros E; Voehringer P; Buerger E
Synapse; 2010 Jul; 64(7):533-41. PubMed ID: 20196139
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
16. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
17. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
18. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Porter MC; Appiah-Kubf LS; Chaudhuri KR
Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
[TBL] [Abstract][Full Text] [Related]
20. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Kvernmo T; Härtter S; Burger E
Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
